Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,953 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients.
Weng CD, Liu KJ, Jin S, Su JW, Yao YH, Zhou CZ, Li YF, Chen ZX, Chen HJ, Li YY, Tang KJ, Yang JJ. Weng CD, et al. Among authors: chen hj. Transl Lung Cancer Res. 2024 Oct 31;13(10):2538-2548. doi: 10.21037/tlcr-24-358. Epub 2024 Oct 28. Transl Lung Cancer Res. 2024. PMID: 39507030 Free PMC article.
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
Li A, Chen HJ, Yang JJ. Li A, et al. Among authors: chen hj. Clin Lung Cancer. 2023 Jan;24(1):82-88. doi: 10.1016/j.cllc.2022.09.009. Epub 2022 Sep 30. Clin Lung Cancer. 2023. PMID: 36333268 Clinical Trial.
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. Tu HY, et al. Among authors: chen zh, chen hj. Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7. Lung Cancer. 2017. PMID: 29173773 Review.
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.
Cheng JT, Yao YH, Gao YE, Zhang SL, Chen HJ, Wang Z, Yan HH, Zhou Q, Tu HY, Zhang XC, Su J, Xie Z, Lizaso A, Chen SY, Lin X, Xiang JX, Wu YL, Yang JJ. Cheng JT, et al. Among authors: chen hj, chen sy. Lung Cancer. 2020 Dec;150:97-106. doi: 10.1016/j.lungcan.2020.10.010. Epub 2020 Oct 20. Lung Cancer. 2020. PMID: 33126092
Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
Li XM, Li WF, Lin JT, Yan HH, Tu HY, Chen HJ, Wang BC, Wang Z, Zhou Q, Zhang XC, Su J, Chen RL, Wu YL, Yang JJ. Li XM, et al. Among authors: chen hj, chen rl. Clin Lung Cancer. 2021 Mar;22(2):100-109.e3. doi: 10.1016/j.cllc.2020.11.001. Epub 2020 Nov 17. Clin Lung Cancer. 2021. PMID: 33317922 Clinical Trial.
1,953 results